Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 134,720 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 134,720 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $100.51, for a total value of $13,540,707.20. Following the completion of the sale, the director directly owned 597,047 shares in the company, valued at approximately $60,009,193.97. The trade was a 18.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Thursday, June 25th, Bruce Booth sold 285,684 shares of Kymera Therapeutics stock. The stock was sold at an average price of $121.86, for a total value of $34,813,452.24.
• On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The stock was sold at an average price of $115.39, for a total value of $30,305,683.43.
• On Tuesday, June 23rd, Bruce Booth sold 1,408 shares of Kymera Therapeutics stock. The shares were sold at an average price of $99.98, for a total value of $140,771.84.
• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The stock was sold at an average price of $98.52, for a total value of $24,268,431.60.
• On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.01, for a total transaction of $10,471,246.56.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.38, for a total transaction of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.98, for a total transaction of $1,056,455.18.
• On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The stock was sold at an average price of $103.75, for a total transaction of $3,299,042.50.
• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.08, for a total transaction of $9,008.00.
• On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $116.46 on Friday. The firm has a market cap of $9.58 billion, a PE ratio of -32.62 and a beta of 2.02. The firm has a 50 day simple moving average of $84.43 and a 200-day simple moving average of $82.12. Kymera Therapeutics, Inc. has a 1-year low of $36.65 and a 1-year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. Kymera Therapeutics’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.82) earnings per share. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera announced that enrollment in its Phase 2b BROADEN2 trial of KT-621 for moderate to severe atopic dermatitis was completed nearly six months ahead of schedule, with topline data expected by year-end 2026. The accelerated timeline also supports the company’s broader development plans for KT-621, including a planned Phase 3 start by mid-2027. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
• Positive Sentiment: BTIG Research reaffirmed its buy rating and set a $134 price target, implying additional upside if the clinical program continues to progress. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
• Neutral Sentiment: The company also announced Felix J. Baker, Ph.D. as chairman of the board, a leadership change that may help support oversight but is less likely to move the stock on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D.
• Negative Sentiment: Insider Noah Goodman sold 5,000 shares at $114 each, which can sometimes be viewed as a cautious signal, though the sale was relatively small versus his remaining holdings. Article: Insider transaction filing

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of KYMR. US Bancorp DE increased its position in Kymera Therapeutics by 9.8% during the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after purchasing an additional 166 shares in the last quarter. Glenmede Trust Co. NA raised its holdings in Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after buying an additional 235 shares during the period. Cetera Investment Advisers lifted its position in Kymera Therapeutics by 7.5% during the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock valued at $300,000 after buying an additional 252 shares in the last quarter. Larson Financial Group LLC grew its stake in Kymera Therapeutics by 36.9% during the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after buying an additional 287 shares during the period. Finally, Swiss National Bank grew its stake in Kymera Therapeutics by 0.3% during the first quarter. Swiss National Bank now owns 94,500 shares of the company’s stock worth $7,871,000 after buying an additional 300 shares during the period.

Wall Street Analysts Forecast Growth

KYMR has been the subject of several analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Canaccord Genuity Group started coverage on Kymera Therapeutics in a research note on Wednesday, May 6th. They issued a “buy” rating and a $106.00 price target on the stock. Citigroup lifted their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Jefferies Financial Group began coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 price objective for the company. Finally, Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $117.14.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.